Scanned by

    Norton

    Norton™ Safe Web

    The macrophage migration inhibitory factor (MIF) as a therapeutic and diagnostic target

    The macrophage migration inhibitory factor (MIF) as a therapeutic and diagnostic target

    01:01 |
    Download Here

    You Might Also Like:

    VJOncology at BTOG 2023

    VJOncology at BTOG 2023

    0:34 |
    Combining radiotherapy with novel agents in NSCLC

    Combining radiotherapy with novel agents in NSCLC

    0:47 |
    Active surveillance in localized prostate cancer

    Active surveillance in localized prostate cancer

    4:12 |
    Second-line treatment of mHSPC

    Second-line treatment of mHSPC

    0:38 |
    The use of photopheresis for the treatment of cutaneous T-cell lymphoma

    The use of photopheresis for the treatment of cutaneous T-cell lymphoma

    3:22 |
    Advances in salvage radiotherapy for prostate cancer

    Advances in salvage radiotherapy for prostate cancer

    1:23 |
    Hormone receptor status and tumor subtypes in BRCA-variant breast cancer

    Hormone receptor status and tumor subtypes in BRCA-variant breast cancer

    1:26 |
    Current challenges and key developments in CRC

    Current challenges and key developments in CRC

    4:00 |
    KEYNOTE-775 subgroup analysis in advanced endometrial cancer

    KEYNOTE-775 subgroup analysis in advanced endometrial cancer

    3:28 |
    Biomarker detection for early cancer detection

    Biomarker detection for early cancer detection

    2:03 |
    ETOP clinical trials in EGFR-, KRASG12C- and ALK-mutated NSCLC

    ETOP clinical trials in EGFR-, KRASG12C- and ALK-mutated NSCLC

    2:47 |
    The role of PSMA PET in recurrent prostate cancer

    The role of PSMA PET in recurrent prostate cancer

    3:50 |
    Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancer

    Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancer

    6:09 |
    Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

    Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

    2:58 |
    Metastatic TNBC at ESMO Breast 2024: IMpassion132 and MORPHEUS

    Metastatic TNBC at ESMO Breast 2024: IMpassion132 and MORPHEUS

    1:05 |
    Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC

    Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC

    2:52 |
    MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

    MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

    4:03 |
    Quantifying time toxicity in lung cancer trials with Time Toxicity Units

    Quantifying time toxicity in lung cancer trials with Time Toxicity Units

    1:30 |
    Important biomarkers in luminal type breast cancer and DCIS

    Important biomarkers in luminal type breast cancer and DCIS

    2:28 |
    Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer

    Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer

    1:49 |